Franzusoff Alex, Duke Richard C, King Thomas H, Lu Yingnian, Rodell Timothy C
GlobeImmune, Inc., 12635 E. Montview Blvd, Aurora, CO 80010, USA.
Expert Opin Biol Ther. 2005 Apr;5(4):565-75. doi: 10.1517/14712598.5.4.565.
Immunotherapy for cancer represents an attractive therapeutic target because of its specificity and lack of toxicity, but products investigated so far have been limited by neutralisation, complexity of manufacturing and requirement for patient-specific products. Recombinant yeast cells are capable of stimulating the immune system to produce highly specific and potent cellular responses against target protein antigens with little toxicity. Data from animal models suggest that Tarmogens (yeast-based immunotherapeutics) can elicit protective immunity against xenografted and chemically induced tumours. This concept is now being tested in a Phase I trial in patients with colorectal, pancreatic and non-small cell lung cancers.
